Roche to Use Aposense EarliTest(TM) for Imaging of Apoptosis in Oncology Clinical Trials
November 09, 2010 02:30 ET
|
Aposense
PETACH-TIKVA, ISRAEL--(Marketwire - November 9, 2010) - Aposense Ltd. (TELAVIV: APOS), a world leader in developing diagnostic and therapeutic drugs based on in vivo targeting of apoptosis (programmed...
Aposense Announces Successful Completion of IPO
June 07, 2010 08:52 ET
|
Aposense
PETACH-TIKVA, ISRAEL--(Marketwire - June 7, 2010) - Aposense, a world leader in developing diagnostic and therapeutic drugs based on targeting in vivo apoptosis (programmed cell death), today...
IBA and Aposense Sign Strategic Collaboration to Commercialize Aposense(R) ML-10 for Molecular Imaging of Apoptosis
September 21, 2009 11:45 ET
|
Aposense
LOUVAIN-LA-NEUVE, BELGIUM and PETACH-TIKVA, ISRAEL--(Marketwire - September 21, 2009) - IBA (Ion
Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB), the leading
global provider of PET...
Aposense(R) Imaging Agent Detects Early Cell Death Induced by Radiation in Patients With Brain Metastases
June 16, 2009 13:30 ET
|
Aposense
PETACH-TIKVA, ISRAEL--(Marketwire - June 16, 2009) - An imaging agent used during PET scans
to highlight apoptosis (programmed cell death) appears to help oncologists
detect the effect of radiation...
Aposense(R) ML-10 Technology for Molecular Imaging of Apoptosis to Be Used by GSK in Experimental Oncology Studies
June 08, 2009 08:00 ET
|
Aposense
PETACH-TIKVA, ISRAEL--(Marketwire - June 8, 2009) - Aposense Ltd., the leading developer
of agents targeting apoptosis (programmed cell death) for molecular imaging
and therapy, today announced a...
APOSENSE(R) Apoptosis Imaging Program for Cancer Therapy Monitoring Initiates a Phase II Multi-Center Study at Memorial Sloan-Kettering Cancer Center
December 15, 2008 08:30 ET
|
Aposense Ltd.
PETACH-TIKVA, ISRAEL--(Marketwire - December 15, 2008) - Aposense Ltd., a leading developer of
agents targeting apoptosis (programmed cell death) for molecular imaging
and therapy, today announced...
NST NeuroSurvival Technologies Completes $13.3 Million Financing, Changes Name to Aposense Ltd.
August 20, 2008 07:00 ET
|
Aposense
PETACH-TIKVA, ISRAEL--(Marketwire - August 20, 2008) - NST NeuroSurvival Technologies Ltd.
(NST), the leading developer of agents that target apoptosis (programmed
cell death) for both molecular...
APOSENSE(R) [18F]-ML-10 to Be Radiolabeled by IBA for Multi-Center Clinical Trials
August 13, 2008 12:06 ET
|
NeuroSurvival Technologies Ltd
LOUVAIN-LA-NEUVE, BELGIUM and PETACH-TIKVA, ISRAEL--(Marketwire - August 13, 2008) - IBA (Ion
Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) the leading
global provider of PET...
APOSENSE(R) [18F]-ML-10 for Molecular Imaging of Apoptosis to Proceed to Phase I/II Trials
July 23, 2008 10:25 ET
|
NST NeuroSurvival Technologies
PETCH-TIKVA, ISRAEL--(Marketwire - July 23, 2008) - NST NeuroSurvival Technologies Ltd.
(NST), a clinical phase company developing molecular imaging agents and
drugs that identify and target cells...